Liposomal-encapsulated doxorubicin (Myocet™; D-99) and vinorelbine in previously treated metastatic breast cancer patients: A feasibility study

Tumori

Volumn 94, Issue 5, 2008, Pages 686-690

  Poletti, Paola ^a   Bettini, Anna Cecilia ^a   Caremoli, Elena Rota ^a   Labianca, Roberto ^a   Tondini, Carlo ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Breast cancer; Chemotherapy; Liposomal doxorubicin; Vinorelbine

Indexed keywords

COLONY STIMULATING FACTOR; DOXORUBICIN; LIPOSOME; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; BREAST METASTASIS; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG SAFETY; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HEART FUNCTION; HUMAN; INFECTION; LEUKOPENIA; LIFE EXPECTANCY; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; PERIPHERAL NEUROPATHY; SIDE EFFECT; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 56749128316     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160809400507     Document Type: Article

References (25)

1. Clark GM, Sledge GW Jr, Osborne CK, McGuire WL: Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol, 5: 55-61, 1987.
2. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Budzar AU: Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol, 14: 2197-2205, 1996.
3. Cowan JD, Neidhart J, McClure S, Coltman CA Jr, Gumbart C, MartinoS, HutchiusLF, Stephens RL, Vanghan CB, Osborne CK: Randomized trial of doxorubicin, bisantrene and mitoxantrone in advanced breast cancer: A Southwest Oncology Group study. J Natl Cancer Inst, 83: 1077-1084. 1991.
4. Henderson IC, Allegra JC, Woodcock T, Wolff S, Bryan S, Cartwright K, Dukart G, Henry D: Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol, 7: 560-571, 1987.
5. Ryberg M, Nielsen D, Skovsgaard T, Hansen J, Jensen BV, Dombernowsky P: Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol, 16: 3502-3508, 1998.
6. Doroshow JH: Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res, 43: 460-472, 1983.
7. Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC: Adryamicin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science, 197: 165-167, 1977.
8. Launchbury AP, Habboubi N: Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev, 19: 197-228, 1993.
9. Batist G, Barton J, Chaikin P, Swenson C, Welles L: Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy. Expert Opin Pharmacother, 3: 1739-1751, 2003.
10. Tardi PG, Boman NL, Cullis PR: Liposomal doxorubicin. J Drug Target, 4: 129-140, 1996.
11. Kanter PM, Bullard GA, Ginsberg RA, Pilkiewicz FG, Mayer LD, Cullis PR, Pavelic ZP: Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free doxorubicin in beagle dogs. In vivo, 7: 17-26, 1993.
12. Batist G, Ramakrishnan G, Sekhar Rao C: Reduced cardiotoxicity and preserved antitumour efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized multicenter trial of metastatic breast cancer. J Clin Oncol, 19: 1444-1454, 2001.
13. Harris L, Batist G, Belt R, RoviraD, Navari R, Azamia N, Welles L, Winer E, TLC D-99 Study Group: Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer, 94: 25-36, 2002.
14. Fumoleau P, Delgado FM, Delozier T, Monnier A, Gil Delgado MA, Kerbrat P, Garcia-Girolt E, Keiling R, Namer M, Closon MT: Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol, 11: 1245-1252, 1993.
15. Garcia-Conde J, Lluch A, Martin M: Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol, 5: 854-857, 1994.
16. Romero A, Rabinovich MG, Vallejo CT, Perez JE, Rodriguez R, Cuevas MA, Macchiavelli M, Lacava JA, Langhi M, Romero Acüna L: Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol, 12: 336-341, 1994.
17. Twelves CJ, Dobbs NA, Curnow A, Coleman RE, Stewart AL, Tyrrel CJ, Canney R Rubens RD: A phase II multicenter, UK study of vinorelbine in advanced breast cancer. Br J Cancer, 70: 990-993, 1994.
18. Weber BL, Vogel C, Jones S, Harvey H, Hutchins L, Bigley J, Holneker J: Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol, 13: 2722-2730, 1995.
19. Blomqvist C, Hietanen P, Teerenhovi L, Rissanen P: Vinorelbine and epirubicin in metastatic breast cancer. A dose finding study. Eur J Cancer, 31A: 2406-2408, 1995.
20. Baldini E, Tibaldi C, Chiavacci F, Di Lieto M, Fioretto L, Giallombardo A, Taviani R, Ghezzi R Bolognini A, Conte P: Epirubicin/vinorelbine as first-line therapy in metastatic breast cancer. Breast Cancer Res Treat, 49: 129-134, 1998.
21. Ejlertsen B, Henning T, Mouridsen T, Langkjer ST, Andersen J, SjöströmJ, Kyaer M, Scandinavian Breast Group Trial: Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403). J Clin Oncol, 22: 2313-2320, 2004.
22. Ezzat A, Motawy S, Berry J: Pilot study of navelbine and epirubicin for the treatment of inoperable locally advanced and metastatic breast cancer. Ann Oncol, 7: 31 (abstr), 1996.
23. Norris B, Pritchard KI, James K, Myles J, Bennet K, Marlin S, Skillings J, Findlay B, Vandenberg T, Goss P, La Fuille J, Rudinskas L, Lofters W, Trudeau M, Osoba D, Rodgers A: Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA 8. J Clin Oncol, 18: 2385-2394, 2000.
24. Tsuchida Y, Therasse P: Response evaluation criteria in solid tumors (RECIST): New guidelines. Med Pediatr Oncol, 37: 1-3, 2001.
25. World Health Organization: WHO Handbook for reporting results of cancer treatment, pp 1-45, Geneva, Switzerland, 1979.